In line with the growing awareness of the importance of fat browning and modulation of TIME, especially by mirabegron, in cancer, our findings show that mirabegron has both risks and benefits in association with RCC progression and may influence tumor initiation, supporting further investigations into the regulation of fat browning and TIME by β3-AR agonists in real clinical settings. Here, ADRB3 is linked to renal cell carcinoma.